Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic

J Drugs Dermatol. 2021 May 1;20(5):582-583. doi: 10.36849/JDD.5730.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • COVID-19 / epidemiology*
  • COVID-19 / immunology
  • Clinical Trials, Phase III as Topic / methods
  • Humans
  • Phosphodiesterase 4 Inhibitors / adverse effects
  • Phosphodiesterase 4 Inhibitors / therapeutic use*
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Risk Factors
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Phosphodiesterase 4 Inhibitors
  • Thalidomide
  • apremilast